ReviewWorld journal of gastroenterology2025
Advances in portal hypertension management: Evolution of the Baveno guidelines.
Review in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Advances in the diagnosis and treatment of portal hypertensive gastrointestinal and bile duct disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Recommendations for treatment of viral hepatitis B in 2026 by the Polish Group of Experts for HBV.Clinical and experimental hepatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of portal hypertension has been the focus of the Baveno guidelines since 1990. This article explores the evolution of these recommendations and their impact on clinical practice. Initially reliant on invasive diagnostics such as the hepatic venous pressure gradient, later editions have incorporated non-invasive methods such as elastography and serum biomarkers. Management strategies have evolved substantially. Endoscopic surveillance has shifted from routine annual endoscopy to an individualized approach based on liver stiffness and platelet count. The role of non-selective beta-blockers (NSBBs) in primary prophylaxis has expanded. Endoscopic band ligation has become the preferred alternative for patients intolerant to NSBBs. In secondary prophylaxis, Baveno II replaced sclerotherapy with band ligation, and later guidelines confirmed the superiority of NSBBs combined with ligation. Transjugular intrahepatic portosystemic shunt emerged as the preferred rescue therapy, with early use emphasized in high-risk patients. Ongoing advancements continue to refine diagnostic and therapeutic strategies, further improving patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.